RU2018114705A - Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена - Google Patents

Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена Download PDF

Info

Publication number
RU2018114705A
RU2018114705A RU2018114705A RU2018114705A RU2018114705A RU 2018114705 A RU2018114705 A RU 2018114705A RU 2018114705 A RU2018114705 A RU 2018114705A RU 2018114705 A RU2018114705 A RU 2018114705A RU 2018114705 A RU2018114705 A RU 2018114705A
Authority
RU
Russia
Prior art keywords
compound
alkyl
salt
pharmaceutically acceptable
condition
Prior art date
Application number
RU2018114705A
Other languages
English (en)
Russian (ru)
Inventor
Стивен Джон АТКИНСОН
Эммануэль Юбер Демон
Ли Эндрю ХАРРИСОН
Томас Джордж Кристофер ХЭЙХАУ
Мэттью Дж. ЛИНДОН
Александер Дж. ПРЕСТОН
Джонатан Томас Сиал
Иан Дэвид УОЛЛ
Роберт Дж. Ватсон
Джеймс Майкл Вулвен
Original Assignee
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед filed Critical ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед
Publication of RU2018114705A publication Critical patent/RU2018114705A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018114705A 2015-10-05 2016-10-03 Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена RU2018114705A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237002P 2015-10-05 2015-10-05
US62/237,002 2015-10-05
PCT/EP2016/073532 WO2017060180A1 (en) 2015-10-05 2016-10-03 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
RU2018114705A true RU2018114705A (ru) 2019-11-07

Family

ID=57113320

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018114705A RU2018114705A (ru) 2015-10-05 2016-10-03 Соединения 2-оксо-1,2-дигидропиридин-3,5-дикарбоксамида в качестве ингибиторов бромодомена

Country Status (11)

Country Link
US (1) US10471050B2 (enExample)
EP (1) EP3359531B1 (enExample)
JP (1) JP6832923B2 (enExample)
KR (1) KR20180059551A (enExample)
CN (1) CN108290866B (enExample)
AU (1) AU2016334637A1 (enExample)
BR (1) BR112018006545A2 (enExample)
CA (1) CA2999379A1 (enExample)
ES (1) ES2831322T3 (enExample)
RU (1) RU2018114705A (enExample)
WO (1) WO2017060180A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
EP3353162A1 (en) 2015-09-22 2018-08-01 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
BR112018006545A2 (pt) 2015-10-05 2018-10-16 Glaxosmithkline Ip No 2 Ltd ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
ES2840848T3 (es) 2016-04-07 2021-07-07 Glaxosmithkline Ip No 2 Ltd Derivados de piridilo como inhibidores de bromodominio
KR20190006567A (ko) * 2016-05-24 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체
GB201703282D0 (en) 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
JOP20190192A1 (ar) 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
GB201814167D0 (en) 2018-08-31 2018-10-17 Glaxosmithkline Ip No 2 Ltd Compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
WO2003070277A1 (en) * 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
BR112018006545A2 (pt) 2015-10-05 2018-10-16 Glaxosmithkline Ip No 2 Ltd ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
ES2840848T3 (es) 2016-04-07 2021-07-07 Glaxosmithkline Ip No 2 Ltd Derivados de piridilo como inhibidores de bromodominio
KR20190006567A (ko) 2016-05-24 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체

Also Published As

Publication number Publication date
US20180280368A1 (en) 2018-10-04
EP3359531B1 (en) 2020-08-19
WO2017060180A1 (en) 2017-04-13
BR112018006545A2 (pt) 2018-10-16
EP3359531A1 (en) 2018-08-15
JP6832923B2 (ja) 2021-02-24
US10471050B2 (en) 2019-11-12
CN108290866B (zh) 2020-12-18
AU2016334637A1 (en) 2018-04-12
JP2018529737A (ja) 2018-10-11
ES2831322T3 (es) 2021-06-08
CN108290866A (zh) 2018-07-17
KR20180059551A (ko) 2018-06-04
CA2999379A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
RU2018112312A (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
RU2018142988A (ru) Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена
JP2017508789A5 (enExample)
JP2017505314A5 (enExample)
RU2018105549A (ru) Производные бензодиазепина как ингибиторы rsv
JP2018529737A5 (enExample)
JP2018528942A5 (enExample)
RU2018134948A (ru) Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций
JP2015514808A5 (enExample)
JP2016534148A5 (enExample)
RU2016150486A (ru) Ингибиторы бета-лактамазы
RU2016137181A (ru) Противофиброзные пиридиноны
JP2015522650A5 (enExample)
JP2020532585A5 (enExample)
JP2017523169A5 (enExample)
JP2013532652A5 (enExample)
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
RU2015106434A (ru) Производные типа азаиндазола или диазаиндазола для лечения боли
RU2018133500A (ru) Бензо[B]фураны в качестве ингибиторов бромодомена
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2015123499A (ru) Соединения замещенной триазолбороновой кислоты
RU2018119015A (ru) ИНГИБИТОРЫ ФАКТОРА XIa
JP2019516761A5 (enExample)
JP2018528229A5 (enExample)
JP2020521766A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20191004